Ross Stewart
AstraZeneca (United Kingdom)(GB)Gifu Women's University(JP)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Head and Neck Cancer Studies, Cancer Genomics and Diagnostics, Immunotherapy and Immune Responses
Most-Cited Works
- → Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade(2014)1,281 cited
- → Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery(2016)412 cited
- → Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody(2015)402 cited
- → Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study(2021)384 cited
- → Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade(2017)360 cited
- → Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial(2021)268 cited
- → Development of PARP and Immune-Checkpoint Inhibitor Combinations(2018)257 cited
- → The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer(2014)165 cited
- → Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer(2024)155 cited
- → BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).(2021)106 cited